XOMA Royalty Corporation (NASDAQ: XOMAP, common stock: XOMA) is a biotech royalty aggregator that plays a unique role in the biotech industry by acquiring economic rights to streams of future milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company was originally founded in 1981 as ...XOMA Royalty Corporation (NASDAQ: XOMAP, common stock: XOMA) is a biotech royalty aggregator that plays a unique role in the biotech industry by acquiring economic rights to streams of future milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company was originally founded in 1981 as XOMA Corporation, a traditional biotech company focused on developing and licensing its own drugs. In 2017, under a strategic transformation, it pivoted to become a royalty aggregator, and in July 2024 it was renamed XOMA Royalty Corporation to reflect its new focus. The company is headquartered at 2200 Powell Street, Emeryville, California, and is listed on NASDAQ, with the preferred stock XOMAP trading as an ADR-like security.
XOMA Royalty's business model involves investing in a diversified portfolio of biotech assets, ranging from early-stage (Phase 1 and 2) candidates to late-stage and commercial products. It acquires royalty and milestone revenue streams by licensing its assets to other biotech and pharma companies, acting as a financial partner rather than a drug developer. The portfolio includes over 120 assets, with seven commercial products as of 2024, providing a steady stream of potential milestone payments and royalties. The company's revenue is primarily derived from these royalty streams, with a gross profit margin of 94.3% and a net profit margin of 123.3% (though these figures may be distorted by one-time gains). Key financial metrics include a market cap of approximately $301 million, an enterprise value of $331.6 million, and a price-to-earnings ratio of 15.1. The company has a moderate debt level, with a debt-to-equity ratio of 1.1, and a dividend yield of 8.6%, reflecting its attractive income potential.
The company is led by CEO Owen Patrick Hughes, who also serves as a key executive, with a team of only 14 full-time employees, indicating a lean and highly specialized operation. Other key executives include CFO Jeffrey Trigilio and Chief Investment Officer Brad Sitko. XOMA Royalty's investor relations highlight its role in helping biotech companies achieve their goals by providing capital in exchange for economic rights, and in 2024, the company announced that it would be acquired by Ligand Pharmaceuticals, a transaction that would expand Ligand's royalty portfolio to over 200 assets. This acquisition underscores XOMA's value as a royalty aggregator. Despite its small team, XOMA Royalty has a significant impact on the biotech sector, and its financial performance, including a price-to-book ratio of 2.6 and a return on equity of 32.4%, reflects effective capital deployment. With a focus on both commercial assets and early-stage candidates, XOMA Royalty continues to seek new opportunities to acquire royalty streams, positioning itself as a niche player in the biotech financial landscape.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$52.1M
+83.1%
+760.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$31.7M
+329.4%
-26.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+94.3%
-5.0%
-7.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+21.8%
+115.6%
-102.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+60.8%
+225.3%
-91.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$2.9M
+120.9%
+209.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+5.5%
+111.4%
+112.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
126.5%
-13.0%
-12.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.37x
-34.7%
+6.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, everyone. My name is Kahalani, and I will be your conference operator today. At this time, I would like to welcome you to the XOMA Royalty 2025 Financial Results and Business Highlights Investor Call. [Operator Instructions] At this time, I'd like to turn the call over to Juliane Snowden, Investor Relations.
Juliane Snowden: Good morning, everyone, and welcome to the XOMA Royalty Fourth Quarter and Full Year 2025 Earnings Call. Earlier today, we issued our financial results press release, which is available in the Investor Relations section of our website at www.xoma.com. A replay of this call will be available on our website following the webcast. Joining me today are Owen Hughes, Chief Executive Officer; Brad Sitko, Chief Investment Officer; and Jeff Trigilio, Chief Financial Officer. During today's call, we will review our 2025 financial results, discuss recent business development activity and portfolio updates, and provide commentary on key upcoming catalysts. After our prepared remarks, we will open the call for questions. Before we begin, I would like to remind everyone that statements made during this call that are not historical facts may be considered forward-looking statements within the meaning of federal securities laws. These statements are based on our current expectations and are subject to risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those described or implied in these statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Form 10-K for a discussion of these and other risks. XOMA Royalty undertakes no obligation to update forward-looking statements, except as required by law. And with that, I'll turn the call over to Owen.
Owen Hughes: Thank you very much, Juliane, and good morning, everyone. 2025 was a foundational year for XOMA Royalty as we continue to execute on our strategy of building a diversified portfolio of biotechnology royalty and milestone assets. We are approaching the inflection point when expected cash flows from our royalty receipts alone should cover the core operating costs of the company. Through both traditional royalty and milestone acquisitions as well as innovative transactions, we enhanced the company's prospects by adding 22 assets to the XOMA Royalty portfolio in 2025 in addition to the acquisition of 2 platform technologies that we hope to be able to out-license in order to generate future royalties and milestones. Furthermore, total portfolio receipts surpassed $50 million, including royalty receipts of $34 million, which grew 68% from fiscal year 2024. By maintaining a lean operating structure, we achieved positive cash flow from operations, and we were able to return $16 million of capital through opportunistic share buybacks in 2025, retiring more than 5% of our common stock outstanding. On a go-forward basis, we anticipate maintaining a disciplined approach …
